Study of anti-inflammatory effect of simvastatin in rats
Ranga Satya Venkatesh1*, Lakshmi Deepika Patchva2, Singamma Muppa2

1Department of Pharmacology, Drug store officer, Central Drug store, Andhra Pradesh, India, 2Department of Pharmacology, Dr. Pinnamaneni Siddhartha Institute of Medical Sciences and Research Foundation, chinnaoutpalli, Andhra Pradesh, India,

Received: 26 May 2016
Revised: 04 July 2016
Accepted: 08 July 2016
*Correspondence to:
Dr. Ranga Satya Venkatesh,
Email: drrsvenkatesh25@gmail.com

ABSTRACT
Background: Inflammation is a complex reaction in tissues that consists mainly of response of blood vessels and leukocytes. Simvastatin is a hypolipidemic drug belonging to the class of statins. Statins are competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the rate limiting enzyme in cholesterol synthesis, are widely prescribed for the treatment of hyperlipidemia. This study was conducted to evaluate the anti-inflammatory activity of simvastatin in albino rats using digital plethysmometer.

Methods: Male wistar albino rats weighing between 200-250 gm were selected for the study and rats were randomly divided into groups (control, standard, and test). The anti-inflammatory activity was evaluated by using carrageenan induced paw edema volume by using digital plethysmometer. Control group rats were administered 0.2 ml of normal saline, whereas, test group rats were administered simvastatin 40 mg and standard group diclofenac 50mg as single dose half an hour before injecting 0.1 ml of 1% carrageenan to the sub-plantar region of hind paw of rat. The paw edema of each rat was measured at 0 hour and after 3 hours.

Results: At a dose of 40 mg Simvastatin showed anti-inflammatory effect which is statically highly significant.

Conclusions: However, the above preclinical experiments only give us an idea about the anti-inflammatory activity, but large scale clinical trials are necessary for final assessment.

Keywords: Simvastatin, Diclofenac sodium, Normal saline, Carrageenan, Plethysmometer

INTRODUCTION
Inflammation is a dynamic process by which living tissue reacts to injury, particularly vascular and connective tissue injury. It is a complex reaction in tissues that consists mainly response of blood vessels and leukocytes. The word inflammation is taken from the Latin word "inflammare" meaning burning. It is defined as; “a process which follows sub lethal injury to tissue and ends with complete healing” as proposed by Ebert.

Inflammation has multifactorial causes. Almost anything that injures living tissue can cause inflammation. The vascular and cellular reactions of inflammation are triggered by soluble factors that are produced by various cells or derived from plasma proteins and generated or activated in response to the inflammatory stimulus. Mediators of inflammation are prostaglandins, leukotrienes, histamine, bradykinin, cytokines growth factors; lysosomal contents of neutrophils, reactive oxygen species etc.

Simvastatin is a hypolipidemic drug belonging to the class of statins. It is a lipid-lowering agent, and is derived synthetically from lovastatin (formerly known as mevinclin) which was isolated from Aspergillus terreus.
Simvastatin is chemically modified derivative of lovastatin. It reduces very low density lipoprotein (VLDL), triglycerides (TG) and increases high density lipoprotein cholesterol (HDL-C).

Statins exert beneficial effects beyond cholesterol reduction. They are improvement in endothelial function, decreasing vascular inflammation, inhibiting smooth-muscle proliferation and immunomodulation. In the present study, anti-inflammatory effect of simvastatin was evaluated and it was compared with diclofenac sodium by using digital plethysmometer.

METHODS

The animals used for the study were male albino rats (200-250 g). Animals are housed at central animal house of Dr. Pinnamenani Siddhartha Institute of Medical Sciences and Research foundation which is maintained under standard conditions. The rats are divided into 3 groups, and each group contains 6 rats. A mark is made at the ankle joint (tibio-tarsal joint) of each rat. Initial paw edema of each rat was measured before giving drug by using digital plethysmometer (0 hour reading). And paw edema of each rat was measured at 3 hours after administration of drug.

Chemical

Carrageenan, diclofenac sodium, simvastatin, double distilled water, normal saline, DMSO.

Equipment

Digital plethysmometer, insulin syringes, tuberculin syringes, measuring jar, glass beakers, animal weighing balance, animal cages, cotton.

Carrageenan induced paw edema model

To study the acute and sub-acute phases of inflammation in rats. Carrageenan is a widely used irritant or inflammogen or a phlogistic agent. Chemically, it is a sulphated polysaccharide obtained from sea weed (rhodophyceae). The experimental tissue injury caused by this irritant initiates a cascade of inflammatory events leading to formation of exudates. The inflammation induced by it is biphasic in nature. The first phase is attributed to the release of histamine, 5-hydroxy tryptamine (serotonin) and kinin while the second phase is related to the release of prostaglandins. The well-recognized method of winter et al, 1962 is followed. 1% w/v suspension of carrageenan was prepared freshly in normal saline and injected into sub planter region of left hind paw (usually 0.1 ml in rats). In control groups animal 0.2 ml normal saline, standard group 50 mg of diclofenac sodium and in test group 40 mg simvastatin were injected intraperitonally half an hour before injecting 0.1 ml of 1% freshly prepared carrageenan to the sub-planter region of left hind paw and the paw edema of each rat is measured after 3 hours.

Difference in rat paw volume and % reduction in paw edema was calculated using the following formula:

% Reduction in edema= ([Mean edema in control group - Mean edema in drug treated group]/Mean edema in control group)×100.

The readings were recorded by using a digital plethysmometer. Results are tabulated and “unpaired t-test” is used to find out the statistical difference in between the standard and test group animals.

RESULTS

Table 1: Volume of paw edema in (ml) in three groups at 0 and 3 hours.

| Group | Drug       | Dose     | Paw edema in ml 0 hours (mean±SD) | Paw edema in ml 3 hours (mean±SD) |
|-------|------------|----------|----------------------------------|----------------------------------|
| I     | Normal saline (control) | 0.2 ml | 1.43±0.069                      | 2.23±0.155                      |
| II    | Simvastatin (test)    | 40 mg   | 1.23±0.017                      | 1.27±0.018                      |
| III   | Diclofenac (standard) | 50 mg   | 1.42±0.083                      | 1.75±0.097                      |

In the given table statistical tools have not been applied. I have used the un-paired student’s t-test for evaluation of the results. After comparing the results there is a difference in the rat paw volume in test versus control and standard versus control. Simvastatin shows significant reduction in rat paw edema (Figure 1).

Results show

- Control group with 0.2 ml of normal saline there was no decrease in rat paw edema.
• In standard group 50mg of Diclofenac showed significant inhibition of rat paw edema compared to normal saline
• In test group 40mg of Simvastatin showed significant inhibition of rat paw edema compared to standard Diclofenac.

Table 2: Comparison between simvastatin 40 mg and diclofenac 50 mg after 0 and 3 hours.

| Group  | Drug       | Dose | Paw edema in ml 0 hours (mean ±SD) | Paw edema in ml 3 hours (mean±SD) |
|--------|------------|------|------------------------------------|-----------------------------------|
| I      | Simvastatin (test) | 40 mg | 1.23±0.017                         | 1.27±0.018                        |
| II     | Diclofenac (standard) | 50 mg | 1.42±0.083                         | 1.75±0.097                        |

When the two drugs simvastatin 40 mg and diclofenac 50 mg were compared and the results are evaluated. Simvastatin was found to have anti-inflammatory activity which was highly significant (p<0.01).

DISCUSSION

This study comprises HMG-COA reductase inhibitor - Simvastatin tested and compared for its anti-inflammatory activity with a standard drug - diclofenac (non-selective COX inhibitor) by one of the acute method i.e., rat paw edema method. The current study demonstrates significant anti-inflammatory activity, by reduction in carrageen induced paw edema method. The percentages of rat paw inhibition of standard and test drug at 0 and 3 hours are 0.70% and 21.52% and 13.99% and 43.05% respectively (Figure 2).

The possible mechanism of anti-inflammatory activity of simvastatin is probably related to inhibition of the production pro-inflammatory mediators. It is difficult to define in vivo the specific molecular mechanism by which statins affect the cell migration, because of complexity of the cholesterol synthesis. Statins interrupt the pro-inflammatory signalling by down-regulation of Rho-related protein activation. Simvastatin requires peroxisome proliferator-activated receptor (PPAR) α expression to exert its anti-inflammatory effects in in-vivo models of acute local inflammation and in-vitro in macrophages and neutrophils.

CONCLUSION

This study was carried out to evaluate the anti-inflammatory property of Simvastatin on rat hind paw edema using digital plethysmometer. At a dose of 40 mg Simvastatin showed anti-inflammatory effect which is statically highly significant. However, the above preclinical experiments only give us an idea about the anti-inflammatory activity, but large scale clinical trials are necessary for final assessment.

ACKNOWLEDGEMENTS

Authors are very grateful to Dr. M. Singamma, Professor and HOD, Dept. of Pharmacology, Dr. PSIMS and RF for her valuable guidance for this study.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee, Dr. PSIMS and RF

REFERENCES

1. Kumar V, Abbas AK, Nelson F, Richard NM. Acute and chronic inflammation. Robbins basic pathology, 8th edition; WB Saunders Co; 2007:31-58.
2. Goodman and Gillman, Anti-inflammatory, Antipyretic and Analgesic agents; Pharmacotherapy of Gout, chapter 34, The Pharmacological basis of Therapeutics, 12th edition, The Pharmacological basis of therapeutics, 12th edition, The Mac Graw Hill companies inc; 2011:986-987.
3. Tripathi KD. Hypolipaemidic drugs and plasma expanders, Chapter-45. Essential of Medical Pharmacology, 7th edition. Jaypee brother publishers; 2013:638.
4. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89-118.
5. Evans M, Roberts A, Davies S, Rees A. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. Drugs. 2004;64:1181-96.
6. Srivastava K. Drugs for dyslipidaemia, section 5, a complete textbook for medical pharmacology volume 1, 1st edition, Avichal Publishing company; 2012:327.
7. Anderson WAD. Inflammation and healing. pathology, 9th Edition, C.V. Mosby co. 1990;1:67.
8. Di Rosa M, Sorrentino L. Biological properties of carrageenan. J Pharma Pharmacol. 1972;89:102.
9. Gosh MN. Experimental pharmacology.5th edition. Hilton and company. Gosh S.K publisher; 2007:120-123.

Cite this article as: Venkatesh RS, Patchva LD, Muppa S. Study of anti-inflammatory effect of simvastatin in rats. Int J Basic Clin Pharmacol 2016;5:1520-3.